A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients with Acute Myelogenous Leukemia (AML).

Trial Profile

A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients with Acute Myelogenous Leukemia (AML).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs AKN 028 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Akinion Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2016 Status changed from recruiting to discontinued as two patients have experienced serious liver events related to AKN-028, The risk-benefit balance was judged to be negative as reported by ClinicalTrials.gov.
    • 02 Feb 2016 Planned End Date changed from 1 Sep 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 02 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top